{"id":62649,"date":"2026-04-08T21:21:50","date_gmt":"2026-04-08T13:21:50","guid":{"rendered":"https:\/\/flcube.com\/?p=62649"},"modified":"2026-04-08T21:21:51","modified_gmt":"2026-04-08T13:21:51","slug":"joincare-pharmaceutical-receives-nmpa-approval-to-initiate-jkn2401-clinical-study-in-crswnp-expanding-tslp-targeting-biologic-development-across-respiratory-indications","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=62649","title":{"rendered":"Joincare Pharmaceutical Receives NMPA Approval to Initiate JKN2401 Clinical Study in CRSwNP, Expanding TSLP-Targeting Biologic Development Across Respiratory Indications"},"content":{"rendered":"\n<p><strong>Joincare Pharmaceutical Group Industry Co., Ltd (<a href=\"https:\/\/www.google.com\/finance\/quote\/600380:SHA\">SHA: 600380<\/a>)<\/strong> announced that China&#8217;s <strong>National Medical Products Administration (NMPA)<\/strong> has approved the company to initiate a clinical study of <strong>JKN2401<\/strong>, an innovative biologic agent targeting <strong>thymic stromal lymphopoietin (TSLP)<\/strong>, for the treatment of <strong>chronic rhinosinusitis with nasal polyps (CRSwNP)<\/strong>. The TSLP inhibitor is simultaneously advancing in a Phase III study for <strong>chronic obstructive pulmonary disease (COPD)<\/strong>, positioning Joincare as a key player in upstream inflammatory pathway modulation.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-development-program-overview\">Development Program Overview<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Parameter<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>Joincare Pharmaceutical Group Industry Co., Ltd (SHA: 600380)<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>JKN2401 \u2013 TSLP-targeting biologic agent<\/td><\/tr><tr><td><strong>Primary Target<\/strong><\/td><td>Thymic stromal lymphopoietin (TSLP)<\/td><\/tr><tr><td><strong>New Indication<\/strong><\/td><td>Chronic rhinosinusitis with nasal polyps (CRSwNP)<\/td><\/tr><tr><td><strong>Regulatory Status<\/strong><\/td><td>NMPA clinical study approval (April 2026)<\/td><\/tr><tr><td><strong>Concurrent Development<\/strong><\/td><td>Phase III study in chronic obstructive pulmonary disease (COPD)<\/td><\/tr><tr><td><strong>Therapeutic Approach<\/strong><\/td><td>Upstream intervention in inflammatory cascade<\/td><\/tr><tr><td><strong>Development Stage<\/strong><\/td><td>Early clinical (CRSwNP), Phase III (COPD)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-drug-mechanism-amp-scientific-rationale\">Drug Mechanism &amp; Scientific Rationale<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-tslp-target-validation\">TSLP Target Validation<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Upstream Cytokine<\/strong>: TSLP is a key epithelial-derived cytokine positioned at the apex of multiple inflammatory cascade pathways<\/li>\n\n\n\n<li><strong>Disease Relevance<\/strong>: Plays critical role in onset and progression of airway inflammation and CRSwNP<\/li>\n\n\n\n<li><strong>Therapeutic Window<\/strong>: Upstream targeting potentially provides broader anti-inflammatory effects versus downstream cytokine inhibition<\/li>\n\n\n\n<li><strong>Clinical Precedent<\/strong>: TSLP inhibition validated by Tezepelumab&#8217;s success in asthma and other type 2 inflammatory diseases<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-mechanism-of-action\">Mechanism of Action<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Pathway Blockade<\/strong>: JKN2401 blocks TSLP signaling pathway at the upstream stage of inflammatory response<\/li>\n\n\n\n<li><strong>Disease Modification<\/strong>: Expected to intervene in disease process rather than merely treating symptoms<\/li>\n\n\n\n<li><strong>Recurrence Prevention<\/strong>: Potential to reduce risk of disease recurrence through sustained pathway inhibition<\/li>\n\n\n\n<li><strong>Symptom Improvement<\/strong>: Comprehensive improvement in nasal congestion, polyp burden, and quality of life measures<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-dual-indication-development-strategy\">Dual-Indication Development Strategy<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-crswnp-clinical-program\">CRSwNP Clinical Program<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Study Design<\/strong>: Initial clinical study following NMPA approval<\/li>\n\n\n\n<li><strong>Patient Population<\/strong>: Adults with chronic rhinosinusitis with nasal polyps inadequately controlled by standard therapies<\/li>\n\n\n\n<li><strong>Primary Endpoints<\/strong>: Likely nasal polyp score, nasal congestion\/obstruction, and endoscopic appearance<\/li>\n\n\n\n<li><strong>Development Timeline<\/strong>: Early-stage program with potential for accelerated development based on COPD data<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-copd-phase-iii-program\">COPD Phase III Program<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Advanced Development<\/strong>: Currently in Phase III clinical trials<\/li>\n\n\n\n<li><strong>Strategic Priority<\/strong>: COPD represents larger market opportunity with significant unmet need<\/li>\n\n\n\n<li><strong>Data Read-through<\/strong>: Positive COPD results could accelerate CRSwNP development<\/li>\n\n\n\n<li><strong>Regulatory Synergy<\/strong>: Shared safety database and manufacturing platform across indications<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-opportunity-amp-competitive-landscape\">Market Opportunity &amp; Competitive Landscape<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-crswnp-treatment-gap\">CRSwNP Treatment Gap<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Prevalence<\/strong>: Affects 2-4% of general population with higher rates in specific subgroups<\/li>\n\n\n\n<li><strong>Current Therapies<\/strong>: Limited to corticosteroids, surgery, and emerging biologics with mixed efficacy<\/li>\n\n\n\n<li><strong>Unmet Need<\/strong>: High recurrence rates post-surgery and inadequate medical management options<\/li>\n\n\n\n<li><strong>Biologic Penetration<\/strong>: Growing but still limited adoption of biologic therapies in CRSwNP<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-tslp-competitive-positioning\">TSLP Competitive Positioning<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Market Leaders<\/strong>: Tezepelumab (AstraZeneca\/Amgen) established in asthma with expanding indications<\/li>\n\n\n\n<li><strong>Differentiation Opportunity<\/strong>: Joincare&#8217;s JKN2401 may offer alternative dosing, pricing, or patient selection advantages<\/li>\n\n\n\n<li><strong>Chinese Innovation<\/strong>: First domestically developed TSLP inhibitor with potential local market advantages<\/li>\n\n\n\n<li><strong>Global Potential<\/strong>: Success in China could support international expansion and partnership opportunities<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-implications-for-joincare\">Strategic Implications for Joincare<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-portfolio-diversification\">Portfolio Diversification<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Biologic Capability<\/strong>: Demonstrates successful transition from traditional pharmaceuticals to biologic development<\/li>\n\n\n\n<li><strong>Respiratory Leadership<\/strong>: Establishes Joincare as comprehensive respiratory disease player<\/li>\n\n\n\n<li><strong>Innovation Credentials<\/strong>: Validates internal R&amp;D capabilities in cutting-edge inflammatory pathway targets<\/li>\n\n\n\n<li><strong>Commercial Synergy<\/strong>: Potential for unified commercial approach across upper and lower airway diseases<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-regulatory-amp-commercial-advantages\">Regulatory &amp; Commercial Advantages<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>NMPA Support<\/strong>: Clinical approval reflects regulatory confidence in development plan<\/li>\n\n\n\n<li><strong>Local Manufacturing<\/strong>: Domestic production capabilities provide supply chain security<\/li>\n\n\n\n<li><strong>Reimbursement Strategy<\/strong>: Dual indication approach enhances National Reimbursement Drug List (NRDL) negotiation position<\/li>\n\n\n\n<li><strong>Physician Relationships<\/strong>: Established commercial infrastructure can rapidly deploy new respiratory biologics<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-development-risk-assessment\">Development Risk Assessment<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-technical-considerations\">Technical Considerations<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Biologic Complexity<\/strong>: Manufacturing and quality control requirements for biologic agents<\/li>\n\n\n\n<li><strong>Immunogenicity Risk<\/strong>: Potential for anti-drug antibodies affecting long-term efficacy<\/li>\n\n\n\n<li><strong>Dosing Optimization<\/strong>: Route of administration and frequency optimization for CRSwNP indication<\/li>\n\n\n\n<li><strong>Patient Selection<\/strong>: Biomarker strategies to identify optimal responders<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-market-risks\">Market Risks<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Competitive Pressure<\/strong>: Established and emerging TSLP inhibitors creating competitive intensity<\/li>\n\n\n\n<li><strong>Pricing Pressure<\/strong>: Biologic pricing scrutiny in Chinese healthcare system<\/li>\n\n\n\n<li><strong>Adoption Barriers<\/strong>: Physician education and patient access challenges for novel biologics<\/li>\n\n\n\n<li><strong>Regulatory Evolution<\/strong>: Changing NMPA requirements for biologic approvals<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-forward-development-pathway\">Forward Development Pathway<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>CRSwNP Study Initiation<\/strong>: Expected to begin enrollment within 3-6 months<\/li>\n\n\n\n<li><strong>Phase I\/II Design<\/strong>: Likely adaptive design leveraging COPD safety data<\/li>\n\n\n\n<li><strong>Combination Strategies<\/strong>: Potential exploration with intranasal corticosteroids<\/li>\n\n\n\n<li><strong>Biomarker Development<\/strong>: Companion diagnostic strategies to optimize patient selection<\/li>\n\n\n\n<li><strong>Global Expansion<\/strong>: International clinical trial planning contingent on Chinese success<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward-Looking Statements<\/strong><br>This brief contains forward-looking statements regarding clinical development, regulatory approvals, and commercial potential. Actual results may differ due to risks including clinical trial outcomes, regulatory decisions, and competitive dynamics.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/600380_20260408_8OFY.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 600380_20260408_8OFY.\"><\/object><a id=\"wp-block-file--media-9cfeae59-8fdc-4896-9a6d-7887ecc483f1\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/600380_20260408_8OFY.pdf\">600380_20260408_8OFY<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/600380_20260408_8OFY.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-9cfeae59-8fdc-4896-9a6d-7887ecc483f1\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Joincare Pharmaceutical Group Industry Co., Ltd (SHA: 600380) announced that China&#8217;s National Medical Products Administration&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[62,676,965],"class_list":["post-62649","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-clinical-trial-approval-initiation","tag-joincare-pharmaceutical","tag-sha-600380"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.3) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Joincare Pharmaceutical Receives NMPA Approval to Initiate JKN2401 Clinical Study in CRSwNP, Expanding TSLP-Targeting Biologic Development Across Respiratory Indications - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Joincare Pharmaceutical Group Industry Co., Ltd (SHA: 600380) announced that China&#039;s National Medical Products Administration (NMPA) has approved the company to initiate a clinical study of JKN2401, an innovative biologic agent targeting thymic stromal lymphopoietin (TSLP), for the treatment of chronic rhinosinusitis with nasal polyps (CRSwNP). The TSLP inhibitor is simultaneously advancing in a Phase III study for chronic obstructive pulmonary disease (COPD), positioning Joincare as a key player in upstream inflammatory pathway modulation.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=62649\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Joincare Pharmaceutical Receives NMPA Approval to Initiate JKN2401 Clinical Study in CRSwNP, Expanding TSLP-Targeting Biologic Development Across Respiratory Indications\" \/>\n<meta property=\"og:description\" content=\"Joincare Pharmaceutical Group Industry Co., Ltd (SHA: 600380) announced that China&#039;s National Medical Products Administration (NMPA) has approved the company to initiate a clinical study of JKN2401, an innovative biologic agent targeting thymic stromal lymphopoietin (TSLP), for the treatment of chronic rhinosinusitis with nasal polyps (CRSwNP). The TSLP inhibitor is simultaneously advancing in a Phase III study for chronic obstructive pulmonary disease (COPD), positioning Joincare as a key player in upstream inflammatory pathway modulation.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=62649\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-08T13:21:50+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-04-08T13:21:51+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62649#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62649\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Joincare Pharmaceutical Receives NMPA Approval to Initiate JKN2401 Clinical Study in CRSwNP, Expanding TSLP-Targeting Biologic Development Across Respiratory Indications\",\"datePublished\":\"2026-04-08T13:21:50+00:00\",\"dateModified\":\"2026-04-08T13:21:51+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62649\"},\"wordCount\":754,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Clinical trial approval \\\/ initiation\",\"Joincare Pharmaceutical\",\"SHA: 600380\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=62649#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62649\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=62649\",\"name\":\"Joincare Pharmaceutical Receives NMPA Approval to Initiate JKN2401 Clinical Study in CRSwNP, Expanding TSLP-Targeting Biologic Development Across Respiratory Indications - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-04-08T13:21:50+00:00\",\"dateModified\":\"2026-04-08T13:21:51+00:00\",\"description\":\"Joincare Pharmaceutical Group Industry Co., Ltd (SHA: 600380) announced that China's National Medical Products Administration (NMPA) has approved the company to initiate a clinical study of JKN2401, an innovative biologic agent targeting thymic stromal lymphopoietin (TSLP), for the treatment of chronic rhinosinusitis with nasal polyps (CRSwNP). The TSLP inhibitor is simultaneously advancing in a Phase III study for chronic obstructive pulmonary disease (COPD), positioning Joincare as a key player in upstream inflammatory pathway modulation.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62649#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=62649\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62649#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Joincare Pharmaceutical Receives NMPA Approval to Initiate JKN2401 Clinical Study in CRSwNP, Expanding TSLP-Targeting Biologic Development Across Respiratory Indications\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Joincare Pharmaceutical Receives NMPA Approval to Initiate JKN2401 Clinical Study in CRSwNP, Expanding TSLP-Targeting Biologic Development Across Respiratory Indications - Insight, China&#039;s Pharmaceutical Industry","description":"Joincare Pharmaceutical Group Industry Co., Ltd (SHA: 600380) announced that China's National Medical Products Administration (NMPA) has approved the company to initiate a clinical study of JKN2401, an innovative biologic agent targeting thymic stromal lymphopoietin (TSLP), for the treatment of chronic rhinosinusitis with nasal polyps (CRSwNP). The TSLP inhibitor is simultaneously advancing in a Phase III study for chronic obstructive pulmonary disease (COPD), positioning Joincare as a key player in upstream inflammatory pathway modulation.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=62649","og_locale":"en_US","og_type":"article","og_title":"Joincare Pharmaceutical Receives NMPA Approval to Initiate JKN2401 Clinical Study in CRSwNP, Expanding TSLP-Targeting Biologic Development Across Respiratory Indications","og_description":"Joincare Pharmaceutical Group Industry Co., Ltd (SHA: 600380) announced that China's National Medical Products Administration (NMPA) has approved the company to initiate a clinical study of JKN2401, an innovative biologic agent targeting thymic stromal lymphopoietin (TSLP), for the treatment of chronic rhinosinusitis with nasal polyps (CRSwNP). The TSLP inhibitor is simultaneously advancing in a Phase III study for chronic obstructive pulmonary disease (COPD), positioning Joincare as a key player in upstream inflammatory pathway modulation.","og_url":"https:\/\/flcube.com\/?p=62649","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-04-08T13:21:50+00:00","article_modified_time":"2026-04-08T13:21:51+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=62649#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=62649"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Joincare Pharmaceutical Receives NMPA Approval to Initiate JKN2401 Clinical Study in CRSwNP, Expanding TSLP-Targeting Biologic Development Across Respiratory Indications","datePublished":"2026-04-08T13:21:50+00:00","dateModified":"2026-04-08T13:21:51+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=62649"},"wordCount":754,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Clinical trial approval \/ initiation","Joincare Pharmaceutical","SHA: 600380"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=62649#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=62649","url":"https:\/\/flcube.com\/?p=62649","name":"Joincare Pharmaceutical Receives NMPA Approval to Initiate JKN2401 Clinical Study in CRSwNP, Expanding TSLP-Targeting Biologic Development Across Respiratory Indications - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-04-08T13:21:50+00:00","dateModified":"2026-04-08T13:21:51+00:00","description":"Joincare Pharmaceutical Group Industry Co., Ltd (SHA: 600380) announced that China's National Medical Products Administration (NMPA) has approved the company to initiate a clinical study of JKN2401, an innovative biologic agent targeting thymic stromal lymphopoietin (TSLP), for the treatment of chronic rhinosinusitis with nasal polyps (CRSwNP). The TSLP inhibitor is simultaneously advancing in a Phase III study for chronic obstructive pulmonary disease (COPD), positioning Joincare as a key player in upstream inflammatory pathway modulation.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=62649#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=62649"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=62649#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Joincare Pharmaceutical Receives NMPA Approval to Initiate JKN2401 Clinical Study in CRSwNP, Expanding TSLP-Targeting Biologic Development Across Respiratory Indications"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/62649","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=62649"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/62649\/revisions"}],"predecessor-version":[{"id":62652,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/62649\/revisions\/62652"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=62649"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=62649"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=62649"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}